← Oncology Approval Tracker

FDA DECISION ·

Opdivo + Yervoy

nivolumab + ipilimumab · Bristol Myers Squibb

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line treatment for metastatic non-small cell lung cancer with tumor PD-L1 expression of at least 1% by an FDA-approved test and no EGFR or ALK genomic tumor aberrations.

LAMPGEN ANALYSIS

Why it matters

Added a first-line chemotherapy-free dual immunotherapy regimen for this PD-L1-defined population.

What research teams should watch

Verify PD-L1 and driver results before treatment and keep immune toxicity triage available between visits.

PRIMARY RECORDS

Sources